Long COVID Definition, Symptoms, Risk Factors, Epidemiology and Autoimmunity: A Narrative Review DOI Creative Commons
Paweł Kozłowski, Aleksandra Leszczyńska, Olga Ciepiela

et al.

American Journal of Medicine Open, Journal Year: 2024, Volume and Issue: 11, P. 100068 - 100068

Published: Feb. 14, 2024

The virus called SARS-CoV-2 emerged in 2019 and quickly spread worldwide, causing COVID-19. It has greatly impacted on everyday life, healthcare systems, the global economy. In order to save as many lives possible, precautions such social distancing, quarantine, testing policies were implemented, effective vaccines developed. A growing amount of data collected worldwide allowed characterization this new disease, which turned out be more complex than other common respiratory tract infections. An increasing number convalescents presented with a variety non-specific symptoms emerging after acute infection. This possible health problem was identified labelled long COVID. Since then, great effort been made by clinicians scientific community understand underlying mechanisms develop preventive measures treatment. role autoimmunity induced infection development COVID is discussed review. We aim deliver description several conditions an autoimmune background observed COVID-19 convalescents, including Guillain-Barré syndrome, antiphospholipid syndrome related thrombosis, Kawasaki disease highlighting relationship between autoimmunity. However, further studies are required determine its true clinical significance.

Language: Английский

Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group DOI Creative Commons
Francesco Ursini, Piero Ruscitti, Olga Addimanda

et al.

RMD Open, Journal Year: 2023, Volume and Issue: 9(2), P. e003022 - e003022

Published: June 1, 2023

To better define the spectrum of new-onset post-COVID-19 and vaccine inflammatory rheumatic diseases (IRD) from a large multicentric observational study.Consecutive cases IRD encountered during 12-month period satisfying one following inclusion criteria: (a) onset manifestations within 4 weeks SARS-CoV-2 infection or (b) administration COVID-19 vaccines ws recruited.The final analysis cohort comprised 267 patients, which 122 (45.2%) in 145 (54.8%) postvaccine cohort. Distribution categories differed between two cohorts: had higher percentage patients classified as having joint (IJD, 52.5% vs 37.2%, p=0.013) while post-vaccine prevalence polymyalgia rheumatica (PMR, 33.1% 21.3%, p=0.032). No differences were detected diagnosed with connective tissue (CTD 19.7% 20.7%, p=0.837) vasculitis (6.6% 9.0%, p=0.467). Despite short follow-up period, IJD PMR patients' response to first-line therapy was favourable, both groups achieving drop baseline disease activity scores ~30% ~70% respectively.Our article reports largest published date vaccines. Although causality cannot be ascertained, possible clinical is broad includes IJD, PMR, CTD vasculitis.

Language: Английский

Citations

30

Overview of autoantibodies in COVID‐19 convalescents DOI
Krystyna Dobrowolska, Dorota Zarębska‐Michaluk,

Barbara Poniedziałek

et al.

Journal of Medical Virology, Journal Year: 2023, Volume and Issue: 95(6)

Published: June 1, 2023

Abstract Accumulating evidence shows that SARS‐CoV‐2 can potentially trigger autoimmune processes, which be responsible for the long‐term consequences of COVID‐19. Therefore, this paper aims to review autoantibodies reported in COVID‐19 convalescents. Six main groups were distinguished: (i) against components immune system, (ii) cardiovascular (iii) thyroid autoantibodies, (iv) specific rheumatoid diseases, (v) antibodies G‐protein coupled receptors, and (vi) other autoantibodies. The reviewed here clearly highlights infection may induce humoral responses. However, available studies share number limitations, such as: (1) sole presence does not necessarily implicate clinically‐relevant risks, (2) functional investigations rarely performed it is often unknown whether observed are pathogenic, (3) control seroprevalence, healthy, noninfected individuals was reported; thus sometimes detected result or accidental post‐COVID‐19 detection, (4) correlated with symptoms syndrome, (5) size studied small, (6) focused predominantly on adult populations, (7) age‐ sex‐related differences seroprevalence explored, (8) genetic predispositions involved generation during infections investigated, (9) reactions following variants vary clinical course remain unexplored. Further longitudinal advocated assess link between identified particular outcomes

Language: Английский

Citations

28

IgG4 Antibodies Induced by mRNA Vaccines Generate Immune Tolerance to SARS-CoV-2’spike Protein by Suppressing the Immune System DOI Open Access
Vladimir N. Uversky, Elrashdy M. Redwan,

William Makis

et al.

Published: March 27, 2023

Due to the health crisis caused by SARS-CoV-2, creation of a new vaccine platform based on mRNA was implemented. Globally, around 13.32 billion COVID-19 doses diverse platforms have been given, and up this date, 69.7% total population received at least one injection vaccine. Although these vaccines prevent hospitalization severe forms disease, increasing evidence has shown they do not produce sterilizing immunity, allowing people suffer frequent re-infections. Recent research also raised concerns that could induce immune tolerance, which, added virus itself, complicate clinical course infection. Furthermore, recent investigations found high IgG4 levels in who were administered two or more injections vaccines. It suggested an increase protecting role preventing over-activation, similar occurring during successful allergen-specific immunotherapy inhibiting IgE-induced effects. Altogether, suggests reported detected after repeated vaccination with is protective mechanism; rather, it may be part tolerance mechanism spike protein promote unopposed SARS-CoV2 infection replication suppressing natural antiviral responses. IgG4-induced suppression system due can cause autoimmune diseases, promotes cancer growth, myocarditis susceptible individuals.

Language: Английский

Citations

26

The mRNA-LNP vaccines – the good, the bad and the ugly? DOI Creative Commons
Botond Z. Igyártó, Zhen Qin

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Feb. 8, 2024

The mRNA-LNP vaccine has received much attention during the COVID-19 pandemic since it served as basis of most widely used SARS-CoV-2 vaccines in Western countries. Based on early clinical trial data, these were deemed safe and effective for all demographics. However, latest data raise serious concerns about safety effectiveness vaccines. Here, we review some efficacy identified to date. We also discuss potential mechanism observed adverse events related use whether they can be mitigated by alterations this approach.

Language: Английский

Citations

17

Long COVID Definition, Symptoms, Risk Factors, Epidemiology and Autoimmunity: A Narrative Review DOI Creative Commons
Paweł Kozłowski, Aleksandra Leszczyńska, Olga Ciepiela

et al.

American Journal of Medicine Open, Journal Year: 2024, Volume and Issue: 11, P. 100068 - 100068

Published: Feb. 14, 2024

The virus called SARS-CoV-2 emerged in 2019 and quickly spread worldwide, causing COVID-19. It has greatly impacted on everyday life, healthcare systems, the global economy. In order to save as many lives possible, precautions such social distancing, quarantine, testing policies were implemented, effective vaccines developed. A growing amount of data collected worldwide allowed characterization this new disease, which turned out be more complex than other common respiratory tract infections. An increasing number convalescents presented with a variety non-specific symptoms emerging after acute infection. This possible health problem was identified labelled long COVID. Since then, great effort been made by clinicians scientific community understand underlying mechanisms develop preventive measures treatment. role autoimmunity induced infection development COVID is discussed review. We aim deliver description several conditions an autoimmune background observed COVID-19 convalescents, including Guillain-Barré syndrome, antiphospholipid syndrome related thrombosis, Kawasaki disease highlighting relationship between autoimmunity. However, further studies are required determine its true clinical significance.

Language: Английский

Citations

14